Treatment of Crohn's disease with infliximab

American Journal of Health-System Pharmacy

Volumn 58, Issue 4, 2001, Pages 307-319

  Garnett, William R ^a   Yunker, Nancy ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Clinical studies; Crohn's disease; Dosage; Drug interactions; Infliximab; Mechanism of action; Pharmaco economics; Pharmacokinetics; Toxicity

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; ENTEROCUTANEOUS FISTULA; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0035865807     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.4.307     Document Type: Review

References (71)

1. Stenson WF. Inflammatory bowel disease. In: Yamada T, ed. Textbook of gastroenterology. 2nd ed. Philadelphia: Lippincott; 1995:1748-806.
2. Cole AT, Pilkington BJ, McLaughlan J et al. Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of interleukin 8 and leukotriene B4. Gut. 1996; 39:248-54.
3. Hommes DW, Meenan J, de Haas M et al. Soluble Fcγ receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut. 1996; 38:564-7.
4. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol. 1997; 92:559-66.
5. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol. 1992; 14:318-27.
6. Gregor JC, McDonald JWD, Klar N et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis. 1997; 3:265-76.
7. Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106:287-96.
8. Gorard DA, Hunt JB, Payne-James JJ et al. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut. 1993; 34:1198-202.
9. Gonzalez-Huix F, de Leon R, Fernandez-Banares F et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut. 1993; 34:778-82.
10. Greenberg GR. Nutritional management of inflammatory bowel disease. Semin Gastrointest Dis. 1993; 4:69-85.
11. Seidman EG, Boutillier L, Weber AM et al. Elemental diet versus prednisone as primary treatment of Crohn's disease. Gastroenterology. 1986; 90:A1625. Abstract.
12. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol. 1995; 20:117-22.
13. Elton E, Hanauer SB. Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther. 1996; 10:1-22.
14. Stotland BR, Lichtenstein GR. Newer treatments for inflammatory bowel disease. Prim Care. 1996; 23:577-608.
15. Stotland BR, Cirigliano MD, Lichtenstein GR. Medical therapies for inflammatory bowel disease. Hosp Pract (Off Ed). 1998; 33:141-68.
16. Cohen RD, Hanauer SB. Immunomodulatory agents and other medical therapies in inflammatory bowel disease. Curr Opin Gastroenterol. 1995; 11:321-30.
17. Elson CO. The basis of current and future therapy for inflammatory bowel disease. Am J Med. 1996; 100:656-62.
18. Sachar DB. Inflammatory bowel disease: recent advances in pharmacotherapy. Gastrointest Dis Today. 1997; 6:9-15.
19. Prantera C, Berto E, Scribano ML et al. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol. 1998; 30:602-6.
20. Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996; 334:841-8.
21. Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci. 1994; 39:1885-92.
22. Munkholm P, Langholz E, Davidsen V et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994; 35:360-2.
23. Löfberg R. New steroids for inflammatory bowel disease. Inflamm Bowel Dis. 1995; 1:135-41.
24. Summers RW, Switz DK, Sessions JT Jr et al. National Cooperative Crohn's Disease Study, results of drug treatment. Gastroenterology. 1979; 77:847-69.
25. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterohgy. 1999; 117:761-9.
26. Van Deventer SJH. Tumour necrosis factor and Crohn's disease. Gut. 1997; 40:443-8.
27. Van Hogezand RA, Verspaget HW. The future role of anti-tumour necrosis factor-α products in the treatment of Crohn's disease. Drugs. 1998; 86:299-305.
28. McAlindon ME, Mahida YR. Pro-inflammatory cytokines in inflammatory bowel disease. Aliment Pharmacol Ther. 1996; 10(suppl 2):72-4.
29. Reimund J-M, Wittersheim C, Dumont S et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996; 16:144-50.
30. Reinecker H-C, Steffen M, Witthoeft T et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993; 94:174-81.
31. Murch SH, Braegger CP, Walker-Smith JA et al. Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993; 34: 1705-9.
32. Watkins PE, Warren BF, Stephens S et al. Treatment of ulcerative colitis in the cotton-top tamarin using antibody to tumour necrosis factor alpha. Gut. 1997; 40:628-33.
33. + T cells. Immunity. 1994; 1:553-62.
34. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 1993; 36: 1681-90.
35. Thorbecke GJ, Shah R, Leu CH et al. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA. 1992; 89:7375-9.
36. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother. 1994; 15:42-52.
37. Von Mehren M, Weiner LM. Monoclonal antibody-based therapy. Curr Opin Oncol. 1996; 8:493-8.
38. Berkower I. The promise and pitfalls of monoclonal antibody therapeutics. Curr Opin Biotechnol. 1996; 7:622-8.
39. Morrison SL. Genetically engineered (chimeric) antibodies. Hosp Pract. 1989; 24:65-80.
40. Co MS, Queen C. Humanized antibodies for therapy. Nature. 1991; 351:501-2.
41. Remicade (infliximab) product information. Malvern, PA: Centocor; 1998 Aug.
42. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993; 30:1443-53.
43. Scallon BJ, Moore MA, Trinh H et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine. 1995; 7:251-9.
44. Siegel SA, Shealy DJ, Nakada MT et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995; 7:15-25.
45. Cope AP, Londei M, Chu NR et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 1994; 94:749-60.
46. Plevy SE, Landers CJ, Prehn J et al. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol. 1997; 159:6276-82.
47. Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999; 163:1521-8.
48. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70:439-44.
49. Irvine EJ. Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol. 1997; 92(suppl):18S-24S.
50. Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 1997; 337:1029-35.
51. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340:1398-405.
52. D'Haens G, Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999; 116:1029-34.
53. Mary JY, Modigliani R, for the Groupe D'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut. 1989; 30:983-9.
54. Baert FJ, D'Haens GR, Peeters M et al. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999; 116:22-8.
55. Rutgeerts PJ, Van Assche G, D'Haens GR et al. Endoscopic characteristics of the relapse of Crohn's disease after infliximab (Remicade) therapy. Gastroenterology. 2000; 118(suppl 2, pt. 1):A568. Abstract.
56. Schreiber S, Kuehbacher T, Mascheretti S et al. Clinical efficacy of treatment with infliximab in a German multicenter, prospective, open-label trial in refractory Crohn's disease. Gastroenterology. 2000; 118(suppl 2, pt. 1):A568. Abstract.
57. De Vos MM, D'Haens G, Van Gossum A et al. Clinical response to infliximab is associated with a substantial increase in quality of life. Gastroenterology. 2000; 118(suppl 2, pt. 2):A1338. Abstract.
58. Arsenau KO, Gross MP, Bickston SJ et al. Preliminary clinical experience with infliximab in the treatment of refractory and fistulizing Crohn's disease (CD). Gastroenterology. 2000; 118(suppl 2, pt. 1):A565. Abstract.
59. Farrell RJ, Lodhavia PI, Alsahli M et al. Infliximab therapy in 100 Crohn's disease patients: adverse events and clinical efficacy. Gastroenterology. 2000; 118(suppl 2, pt. 1):A566. Abstract.
60. McCabe RP, Schwartz RM, Bebeau V et al. Treatment of Crohn's disease with infliximab - an initial community practice experience. Gastroenterology. 2000; 118(suppl 2, pt. 1):A567. Abstract.
61. Ricart E, Panaccione R, Loftus EV et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Gastroenterology. 2000; 118(suppl 2, pt. 1):A568. Abstract.
62. Toy LS, Marion JF, Scherl EJ et al. Infliximab therapy for Crohn's disease fistulae: number of infusions required for response and time to relapse. Gastroenterology. 2000; 118(suppl 2, pt. 1):A569. Abstract.
63. Lipsky PE. Changing the management of rheumatoid arthritis: new data, new options. Paper presented at American College of Rheumatology 63rd Annual Scientific Meeting. Boston, MA; 1999 Nov 15.
64. Greenstein AJ, Mullin GE, Strauchen JA et al. Lymphoma in inflammatory bowel disease. Cancer. 1992; 69:1119-23.
65. Bickston SJ, Lichtenstein GR, Arseneau KO et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology. 1999; 117:1433-7.
66. Hanauer SB, Schaible TP, DeWoody KL et al. Long-term follow-up of patients treated with infliximab (anti-TNFA antibody) in clinical trials. Gastroenterology. 2000; 118(suppl 2, pt. 1):A566. Abstract.
67. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999; 13(suppl 4):16-22.
68. Shergy W. Paper presented at PROMPT Investigator Meeting. Chicago, IL; 1999 Aug 14.
69. Red Book Update. 2000; 19(10):62.
70. Hanauer SB, Cohen RD, Becker RV et al. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998; 20:1009-28.
71. Kugathasan S, Werlin SL, Aktay N et al. Prolonged duration of response to infliximab in early pediatric Crohn's disease (CD): one year followup. Gastroenterology. 2000; 118(suppl 2, pt. 1):A566-7. Abstract.